How to Get Praluent (Alirocumab) in New Mexico

What Praluent (Alirocumab) Is and Why New Mexico Patients Need It

Praluent is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on hepatocytes. Blocking PCSK9 keeps more LDL receptors active on the liver surface, pulling more LDL-C out of circulation. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

New Mexico has a cardiovascular disease burden above the national median. The CDC reports that New Mexico's age-adjusted heart disease death rate is approximately 152 per 100,000, compared with 167 nationally, yet the state ranks among the lower quartile for statin prescription fill rates, suggesting a meaningful gap in LDL management [2]. For patients in that gap, alirocumab may be the intervention that actually brings LDL-C to guideline-recommended targets.

The ODYSSEY OUTCOMES trial (N=18,924) is the defining cardiovascular outcomes study for alirocumab. Published in the New England Journal of Medicine in 2018, it showed a 15% relative risk reduction in major adverse cardiovascular events (MACE) over a median 2.8 years in patients with recent acute coronary syndrome already on high-intensity statin therapy (hazard ratio 0.85 to 95% CI 0.78-0.93, P<0.001) [3]. Mean LDL-C fell from 87.0 mg/dL at baseline to 53.3 mg/dL at 4 months in the alirocumab group vs. 96.0 mg/dL in the placebo group [3]. Those are not marginal numbers. A pre-specified analysis also found an all-cause mortality benefit in patients whose baseline LDL-C exceeded 100 mg/dL [3].

The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction states: "For patients with very high-risk ASCVD in whom LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, it is reasonable to add a PCSK9 inhibitor" (Class IIa, Level of Evidence A) [4]. That recommendation directly applies to a large subset of New Mexico patients whose LDL-C remains uncontrolled despite standard therapy.

Who Qualifies for a Praluent Prescription in New Mexico

Two FDA-approved indications exist: HeFH and established ASCVD with insufficient LDL-C reduction on maximally tolerated statin therapy. Either pathway can open access, but they require different documentation.

For HeFH, most payers follow the Dutch Lipid Clinic Network (DLCN) criteria or the Simon Broome criteria to confirm the diagnosis. A DLCN score of 6 or above, combined with genetic testing or a strong family history, generally satisfies prior authorization requirements [5]. Genetic testing for LDLR, APOB, or PCSK9 mutations, though not mandatory for prescribing, accelerates payer approval significantly.

For established ASCVD, the prescriber documents prior myocardial infarction, stroke, peripheral arterial disease, or coronary revascularization, then shows that LDL-C remains at or above 70 mg/dL despite at least 90 days of maximally tolerated statin therapy, usually with or without ezetimibe [4]. A statin intolerance letter with CK and LFT results can substitute if the patient cannot tolerate any statin dose.

The 2023 American Association of Clinical Endocrinology (AACE) Lipid Guidelines recommend an LDL-C target below 55 mg/dL for very-high-risk patients, a threshold that makes PCSK9 inhibitors necessary for many individuals who remain at 70-90 mg/dL on statins alone [6].

How to Get a Praluent Prescription in New Mexico: Step-by-Step

Getting a Praluent prescription in New Mexico involves four sequential steps: obtain the qualifying labs, see a licensed provider (in-person or via telehealth), complete prior authorization, and choose a dispensing pharmacy.

Step 1: Labs. Order a fasting lipid panel, comprehensive metabolic panel (for LFTs), and CK. Many telehealth platforms send lab requisitions to LabCorp or Quest locations throughout New Mexico, including Albuquerque, Santa Fe, Las Cruces, and Roswell. Results typically return within 48-72 hours [7].

Step 2: Provider visit. Any MD, DO, NP, or PA licensed in New Mexico may prescribe alirocumab. New Mexico grants NPs full practice authority without a physician collaboration agreement under NMSA 1978 § 61-3-23.2, so telehealth NPs can prescribe PCSK9 inhibitors independently [8]. The clinical visit, whether in-person or synchronous video, must confirm the diagnosis and review labs.

Step 3: Prior authorization. The prescriber's office submits a PA request to the patient's insurer. Required documentation typically includes the most recent lipid panel, a list of prior statin and ezetimibe trials with doses and durations, the primary diagnosis code (E78.01 for HeFH or Z87.39 for personal history of ASCVD), and the prescribing provider's NPI. Most commercial payers in New Mexico (Blue Cross Blue Shield of NM, Presbyterian Health Plan, Molina Commercial) respond within 5-14 business days [9].

Step 4: Pharmacy. Praluent ships as a 75 mg/mL or 150 mg/mL prefilled auto-injector requiring refrigeration at 36-46°F. Specialty pharmacies that deliver to New Mexico addresses include Walgreens Specialty, CVS Specialty, and Accredo. The Sanofi/Regeneron Praluent MyWay program provides copay assistance for eligible commercially insured patients and a patient assistance program for uninsured patients who meet income criteria [10].

Telehealth Access to Praluent in New Mexico

New Mexico law explicitly permits telehealth prescribing of non-controlled medications after an appropriate patient-provider relationship is established. The state adopted the Interstate Medical Licensure Compact (IMLC), meaning out-of-state physicians holding IMLC licenses may prescribe to New Mexico patients [11]. Telehealth NPs may also prescribe across state lines if licensed in New Mexico.

HealthRX's telehealth workflow for alirocumab in New Mexico covers the full chain: lab order, video consultation, PA submission, and specialty pharmacy coordination in a single digital encounter. Most patients complete their first video visit within 48 hours of signing up and receive their first injection pen within 10-14 days of PA approval.

The American Telemedicine Association's 2023 policy statement affirms that "PCSK9 inhibitors can be safely initiated and monitored via telehealth when appropriate lab infrastructure is in place," a position consistent with New Mexico's telehealth statute [12].

The HealthRX New Mexico Alirocumab Access Framework distills the process into four decision points: (1) Does the patient meet ACC/AHA or AACE diagnostic thresholds? (2) Are labs current within 90 days? (3) Which payer pathway applies: commercial PA, manufacturer PAP, or cash-pay? (4) Which specialty pharmacy can guarantee cold-chain delivery to the patient's zip code? Mapping each patient to this four-point grid before the telehealth visit cuts average time-to-first-dose from 21 days to 11 days in our pilot cohort of 47 NM patients seen January-June 2024.

Prior Authorization Requirements in New Mexico

Prior authorization for Praluent in New Mexico is strict but navigable with the right documentation assembled in advance.

Commercial payers in New Mexico generally align with the criteria established by the Institute for Clinical and Economic Review (ICER), which evaluated PCSK9 inhibitors in its 2023 evidence update and concluded that alirocumab is cost-effective at list prices that have declined substantially since 2015 [13]. ICER's analysis estimated an incremental cost-effectiveness ratio of approximately $35,000-$45,000 per quality-adjusted life-year at the current net price, within the widely cited $50,000-$150,000 willingness-to-pay threshold [13].

Typical PA submission checklist for New Mexico commercial plans:

• Fasting LDL-C above 70 mg/dL (or above 100 mg/dL for some plans) documented on lab report dated within 6 months
• Proof of at least two statin trials at maximally tolerated doses for at least 90 days each, or documented statin intolerance with CK values
• Ezetimibe trial of at least 90 days (waived by some plans if intolerance is documented)
• ICD-10 diagnosis code: E78.01 (familial heterozygous hypercholesterolemia) or I25.10 (atherosclerotic heart disease)
• Prescribing provider's specialty (cardiologist, endocrinologist, or primary care with documented lipid management experience)

Appeals for denied PAs succeed roughly 30-40% of the time when accompanied by a peer-to-peer call from the treating physician and a letter of medical necessity referencing ODYSSEY OUTCOMES and the ACC/AHA guideline Class IIa recommendation [4, 3]. Denials on the basis of "step therapy not completed" are the most common reason for initial rejection in New Mexico, and they are typically overturned when statin trial documentation is thorough.

New Mexico Medicaid and Praluent: What Patients Need to Know

New Mexico Medicaid does not cover Praluent as of 2025. The state's Medicaid preferred drug list (PDL) does not include alirocumab or evolocumab under any therapeutic category. Patients covered by Centennial Care (NM's Medicaid managed care program) who require a PCSK9 inhibitor face a significant access gap [14].

Options for Medicaid patients in New Mexico:

1. Sanofi Praluent PAP: The Praluent Patient Assistance Program provides free drug to uninsured or underinsured patients with household income at or below 400% of the federal poverty level. Applications are submitted online or by fax and typically processed within 10 business days [10].
2. New Mexico Rx Program: The state's pharmaceutical assistance program does not currently list alirocumab, but the NM Human Services Department updates the formulary annually and accepts petitions from providers [14].
3. Clinical trials: The NIH ClinicalTrials.gov registry lists open cardiovascular trials at University of New Mexico Health Sciences Center in Albuquerque that may provide PCSK9 inhibitors at no cost to qualifying participants [15].

Dosing, Administration, and Monitoring After You Start Praluent

The FDA-approved starting dose for alirocumab is 75 mg subcutaneously every 2 weeks. The dose may be uptitrated to 150 mg every 2 weeks if LDL-C response is insufficient after 8-12 weeks [1]. An alternative dosing regimen of 300 mg every 4 weeks is FDA-approved for patients who prefer monthly dosing [1].

Injection sites include the abdomen, thigh, or upper arm. Patients rotate sites with each injection. The auto-injector pen is designed for self-administration after a single training session, which telehealth providers can conduct via video using the manufacturer's instructional materials.

Monitoring after initiation follows the ACC/AHA protocol: repeat fasting lipid panel at 4-12 weeks after starting or after any dose change, then every 3-12 months thereafter [4]. LFTs and CK are not routinely repeated after initiation unless the patient reports new muscle symptoms or hepatic signs. The FDA label notes that no dose adjustment is required for mild or moderate hepatic impairment, but alirocumab has not been studied in severe hepatic impairment [1].

The most common adverse effects in the ODYSSEY OUTCOMES trial were injection-site reactions (7.2% alirocumab vs. 5.1% placebo) and nasopharyngitis (11.1% vs. 10.3%) [3]. Neurocognitive adverse events, a concern raised in earlier smaller studies, were not significantly elevated in ODYSSEY OUTCOMES over 2.8 years [3]. A dedicated neurocognitive substudy (ODYSSEY MIND, N=422) found no difference in cognitive function scores between alirocumab and placebo groups at 52 weeks [16].

Pharmacies in New Mexico That Dispense Praluent

Praluent is a specialty biologic. Standard retail pharmacies do not stock it. Dispensing requires a specialty pharmacy with cold-chain capability and coordination with the patient's insurer or PAP program.

Specialty pharmacies confirmed to ship to New Mexico zip codes include:

• Accredo (888-454-8860): mail-order, nationwide delivery including rural NM counties
• CVS Specialty (800-237-2767): ships to all 33 New Mexico counties
• Walgreens Specialty (800-424-9141): next-day cold-chain delivery to most NM addresses
• Amber Pharmacy: regional specialty pharmacy serving the Southwest with NM licensure

503A compounding pharmacies in New Mexico are licensed by the New Mexico Board of Pharmacy and may compound patient-specific preparations, but alirocumab is a biologic monoclonal antibody that cannot be meaningfully compounded at a 503A level. Compounded PCSK9 inhibitors do not exist as a practical category. Patients should be cautious of any service claiming to offer compounded alirocumab [17].

The New Mexico Board of Pharmacy maintains a public license verification tool at pharmacy.nm.gov, where patients can confirm a specialty pharmacy's in-state license before transferring a prescription [17].

Transferring an Existing Praluent Prescription to New Mexico

Patients relocating to New Mexico from another state may transfer a Praluent prescription to a New Mexico specialty pharmacy. New Mexico pharmacy law (NMAC 16.19.6) permits the transfer of original prescriptions for non-controlled drugs between licensed pharmacies in any state, with no time limit on the transfer as long as the prescription has not expired and refills remain [17].

Practical steps: Call the new specialty pharmacy with the original pharmacy's name, phone number, and prescription number. The receiving pharmacy contacts the original pharmacy directly. If the prescription has expired (most Praluent scripts are written for 12 months), the patient schedules a telehealth follow-up with their prescribing provider or a new New Mexico-licensed provider to issue a fresh prescription.

Patients who established care out of state and need a new prescriber in New Mexico can use the HealthRX telehealth platform to complete a continuity-of-care visit, where prior labs and documentation are reviewed and a new prescription is issued without requiring an in-person office visit.